Exhibit 99.1 CONTACTS: Tapestry, Inc. Analysts and Investors: Christina Colone Global Head of Investor Relations 212/946-7252 ccolone@tapestry.com Media: Jennifer Leemann Global Head of Communications 212/631-2797 jleemann@tapestry.com TAPESTRY, INC. REPORTS FISCAL 2025 FOURTH QUARTER AND FULL YEAR RESULTS Link to Download Tapestry's Q4 and Fiscal Year Earnings Presentation, Including Brand Highlights New York, August 14, 2025 – Tapestry, Inc. (NYSE: TPR), a house of iconic accessories and lifestyle brands, ...

PART I FINANCIAL INFORMATION [Item 1. Condensed Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Condensed%20Financial%20Statements%20(Unaudited)) Unaudited **H1 2025** financials reflect a reduced net loss and decreased assets, primarily due to lower **R&D** expenses and the conclusion of collaboration agreements [Condensed Balance Sheets](index=5&type=section&id=Condensed%20Balance%20Sheets) Condensed Balance Sheet Summary (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $50,467 | $57,387 | | Total current assets | $54,675 | $79,215 | | **Total assets** | **$64,371** | **$91,049** | | **Liabilities & Equity** | | | | Total current liabilities | $5,336 | $8,917 | | **Total liabilities** | **$7,352** | **$11,423** | | **Total stockholders' equity** | **$57,019** | **$79,626** | - Total assets decreased from **$91.0 million** at the end of **2024** to **$64.4 million** as of **June 30, 2025**, primarily due to a reduction in cash, cash equivalents, and investments[18](index=18&type=chunk) [Condensed Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Collaboration revenue | $0 | $1,609 | $0 | $2,724 | | Research and development | $8,680 | $19,239 | $18,599 | $35,503 | | General and administrative | $4,352 | $5,332 | $8,822 | $10,227 | | Loss from operations | $(13,032) | $(22,962) | $(27,421) | $(43,006) | | **Net loss** | **$(12,458)** | **$(21,552)** | **$(26,160)** | **$(40,056)** | | Net loss per share | $(0.24) | $(0.42) | $(0.51) | $(0.79) | - Net loss for the second quarter of **2025** was **$12.5 million**, a significant reduction from **$21.6 million** in the same period of **2024**, mainly due to a **55%** decrease in **R&D** expenses[21](index=21&type=chunk) [Condensed Statements of Changes in Stockholders' Equity](index=7&type=section&id=Condensed%20Statements%20of%20Changes%20in%20Stockholders'%20Equity) - Total stockholders' equity decreased from **$79.6 million** at **December 31, 2024**, to **$57.0 million** at **June 30, 2025**, primarily driven by the net loss of **$26.2 million** for the six-month period[23](index=23&type=chunk) [Condensed Statements of Cash Flows](index=8&type=section&id=Condensed%20Statements%20of%20Cash%20Flows) Cash Flow Summary for Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(22,463) | $(27,079) | | Net cash provided by (used in) investing activities | $15,600 | $(38,690) | | Net cash (used in) provided by financing activities | $(57) | $836 | | **Net decrease in cash and cash equivalents** | **$(6,920)** | **$(64,933)** | - Cash and cash equivalents decreased by **$6.9 million** during the first six months of **2025**, ending at **$50.5 million**, compared to a much larger decrease of **$64.9 million** in the same period of **2024**, which included significant purchases of investments[25](index=25&type=chunk) [Notes to the Unaudited Interim Condensed Financial Statements](index=9&type=section&id=Notes%20to%20the%20Unaudited%20Interim%20Condensed%20Financial%20Statements) - The company has incurred losses since inception, with an accumulated deficit of **$407.9 million** as of **June 30, 2025**, but management believes current cash of **$50.5 million** is sufficient to fund operations for at least the next twelve months[27](index=27&type=chunk) - All collaboration revenue in **2024** was derived from agreements with **Ono Pharmaceutical** and **ImmunoGen**, both completed by **December 31, 2024**, with no revenue recognized from these agreements in **2025**[36](index=36&type=chunk)[86](index=86&type=chunk)[91](index=91&type=chunk) - On **August 4, 2025**, the company entered into a securities purchase agreement for a private placement expected to provide upfront gross proceeds of approximately **$46 million**, including common stock, pre-funded warrants, and common stock warrants[110](index=110&type=chunk)[113](index=113&type=chunk) R&D Expenses by Program for Six Months Ended June 30 (in thousands) | Program | 2025 | 2024 | | :--- | :--- | :--- | | SL-325 | $4,833 | $363 | | SL-172154 (discontinued) | $2,625 | $16,270 | | Other research and development | $4,859 | $8,204 | | **Total R&D** | **$18,599** | **$35,503** | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the strategic pivot to developing **SL-325**, reduced operating expenses, and liquidity, with a private placement extending funding into **2029** [Overview](index=25&type=section&id=Overview) - The company is now focused on developing **SL-325**, a potentially first-in-class death receptor **3** (**DR3**) antagonist antibody for treating inflammatory bowel disease (**IBD**) and other immune-mediated diseases[116](index=116&type=chunk) - **Shattuck Labs** plans to initiate a **Phase 1** clinical trial for **SL-325** in the third quarter of **2025** and expects to complete enrollment in the full **Phase 1** trial in the second quarter of **2026**[121](index=121&type=chunk) - The company is also developing a series of bispecific antibodies targeting **DR3** and other clinically validated targets, with a lead candidate nomination expected in **2025**[124](index=124&type=chunk)[125](index=125&type=chunk) [Results of Operations](index=30&type=section&id=Results%20of%20Operations) Comparison of Operating Results for Q2 (in thousands) | Metric | Q2 2025 | Q2 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Collaboration Revenue | $0 | $1,609 | $(1,609) | (100.0)% | | R&D Expense | $8,680 | $19,239 | $(10,559) | (54.9)% | | G&A Expense | $4,352 | $5,332 | $(980) | (18.4)% | | **Net Loss** | **$(12,458)** | **$(21,552)** | **$9,094** | **(42.2)%** | Comparison of Operating Results for H1 (in thousands) | Metric | H1 2025 | H1 2024 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Collaboration Revenue | $0 | $2,724 | $(2,724) | (100.0)% | | R&D Expense | $18,599 | $35,503 | $(16,904) | (47.6)% | | G&A Expense | $8,822 | $10,227 | $(1,405) | (13.7)% | | **Net Loss** | **$(26,160)** | **$(40,056)** | **$13,896** | **(34.7)%** | - The decrease in **R&D** expenses for **H1 2025** was primarily due to a **$13.6 million** reduction from the discontinuation of **SL-172154** and a **$4.4 million** decrease in compensation from workforce reductions, offset by a **$4.5 million** increase in spending on **SL-325**[154](index=154&type=chunk) [Liquidity and Capital Resources](index=31&type=section&id=Liquidity%20and%20Capital%20Resources) - The company believes its cash and cash equivalents of **$50.5 million** as of **June 30, 2025**, are sufficient to fund operations into **2027**[162](index=162&type=chunk) - The anticipated proceeds from the **August 2025** Private Placement, combined with current cash, are expected to extend the company's operational funding into **2029**[162](index=162&type=chunk) - The company's Registration Statement on **Form S-3** expired on **July 29, 2025**, halting sales under its **ATM Facility**, and due to its public float, sales are limited to one-third of the market value of its common stock held by non-affiliates until its public float exceeds **$75.0 million**[158](index=158&type=chunk)[159](index=159&type=chunk) [Critical Accounting Policies](index=33&type=section&id=Critical%20Accounting%20Policies) - There have been no material changes to the company's critical accounting policies, including revenue recognition, accrual for **R&D** expenses, and valuation of stock-based awards, compared to those disclosed in the **2024** Annual Report on **Form 10-K**[171](index=171&type=chunk)[174](index=174&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=34&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, the company is not required to provide market risk disclosures - The company is a smaller reporting company and is not required to provide quantitative and qualitative disclosures about market risk[179](index=179&type=chunk) [Item 4. Controls and Procedures](index=35&type=section&id=Item%204.%20Controls%20and%20Procedures) Disclosure controls were effective as of **June 30, 2025**, with no material changes in internal control over financial reporting during **Q2 2025** - Management concluded that as of **June 30, 2025**, the company's disclosure controls and procedures were effective at the reasonable assurance level[180](index=180&type=chunk) - No changes in internal control over financial reporting occurred during the second quarter of **2025** that have materially affected, or are reasonably likely to materially affect, these controls[181](index=181&type=chunk) PART II OTHER INFORMATION [Item 1. Legal Proceedings](index=35&type=section&id=Item%201.%20Legal%20Proceedings) The company reported no legal proceedings as of the reporting date - As of the reporting date, there were no legal proceedings to disclose[183](index=183&type=chunk) [Item 1A. Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors) Key risks include the need for additional funding, potential non-completion of the private placement, and **Nasdaq** minimum bid price non-compliance - The company requires additional funding to complete development of its product candidates, and the **August 2025** Private Placement is subject to closing conditions and may not be completed as expected[185](index=185&type=chunk)[187](index=187&type=chunk) - On **August 8, 2025**, the company received a notice from **Nasdaq** for non-compliance with the minimum bid price rule (**$1.00** per share), with a deadline of **February 4, 2026**, to regain compliance[191](index=191&type=chunk)[192](index=192&type=chunk) - The company is subject to limitations on its ability to sell stock under **Form S-3**, which may restrict sales to no more than one-third of the market value of its common stock held by non-affiliates until its public float exceeds **$75.0 million**[186](index=186&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=37&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities or use of proceeds were reported - None reported[194](index=194&type=chunk) [Item 3. Defaults Upon Senior Securities](index=37&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) No defaults upon senior securities were reported - None reported[194](index=194&type=chunk) [Item 4. Mine Safety Disclosures](index=37&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) No mine safety disclosures were reported - None reported[195](index=195&type=chunk) [Item 5. Other Information](index=37&type=section&id=Item%205.%20Other%20Information) The company received a **Nasdaq** notice for non-compliance with the **$1.00** minimum bid price rule, with a compliance deadline of **February 4, 2026** - On **August 8, 2025**, the company received a notice from **Nasdaq** for failing to meet the minimum bid price requirement of **$1.00** per share for **30** consecutive business days[196](index=196&type=chunk) - The company has a **180-day** compliance period, ending **February 4, 2026**, to regain compliance by having its closing bid price be at least **$1.00** for a minimum of **10** consecutive business days[196](index=196&type=chunk) [Item 6. Exhibits](index=38&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the **Form 10-Q**, including certifications and **Inline XBRL** data files - The exhibits filed with the report include certifications from the **CEO** and **CFO**, and **Inline XBRL** documents[202](index=202&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 001-40582 UNICYCIVE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 81-3638692 (I.R.S. Employ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-34625 SMART POWERR CORP. (Exact name of registrant as specified in its charter) Nevada 90-0093373 (State o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number 1-9330 CORECARD CORPORATION (Exact name of registrant as specified in its charter) | Georgia | 58-1964787 | | --- | --- | | ( ...

[PART I — FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20%E2%80%94%20FINANCIAL%20INFORMATION) This section presents the company's condensed consolidated financial statements and related disclosures [Item 1. Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Condensed%20Consolidated%20Financial%20Statements) The financial statements show decreased assets, increased net loss, and significant cash reduction, raising going concern doubts [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $48.3 million, driven by a significant cash drop, while liabilities and equity remained stable Condensed Consolidated Balance Sheet Highlights (in thousands of USD) | Balance Sheet Item | June 30, 2025 (unaudited) | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash | $2,207 | $8,002 | | Total current assets | $27,903 | $32,198 | | Total assets | $48,268 | $53,425 | | **Liabilities & Equity** | | | | Total current liabilities | $29,218 | $19,704 | | Total liabilities | $41,388 | $44,446 | | Total stockholders' equity | $6,880 | $6,494 | | **Total liabilities and stockholders' equity** | **$48,268** | **$53,425** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Net losses increased to $21.2 million for the six months, driven by higher operating expenses despite a slight revenue increase Statements of Operations Summary (in thousands of USD, except per share data) | Metric | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Total revenue, net | $2,979 | $2,721 | $5,193 | $5,072 | | Total operating expenses | $10,986 | $9,918 | $22,621 | $20,484 | | Loss from operations | $(8,007) | $(7,197) | $(17,428) | $(15,412) | | Net loss | $(10,560) | $(9,628) | $(21,156) | $(18,996) | | Net loss per share | $(10.26) | $(2.66) | $(26.78) | $(7.80) | [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash decreased by $5.8 million, with $13.5 million used in operations and reduced financing activities Cash Flow Summary for Six Months Ended June 30 (in thousands of USD) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(13,509) | $(15,217) | | Net cash used in investing activities | $0 | $(16) | | Net cash provided by financing activities | $7,621 | $24,842 | | **Net increase (decrease) in cash** | **$(5,795)** | **$9,580** | | Cash at beginning of period | $8,002 | $6,469 | | **Cash at end of period** | **$2,207** | **$16,049** | [Notes to Condensed Consolidated Financial Statements](index=13&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail a going concern warning, revenue concentration, debt instruments, and equity transactions - The company has incurred recurring operating losses and has an accumulated deficit of **$367.4 million** as of June 30, 2025. Management has substantial doubt about the company's ability to continue as a going concern as current cash balances are not sufficient to fund operations for the next year[37](index=37&type=chunk)[38](index=38&type=chunk) - The company is highly dependent on two major customers, which accounted for **58%** and **30%** of total revenue for the three months ended June 30, 2025[53](index=53&type=chunk) - The company manages its operations through two segments: human health and animal health, with the human health segment focused on developing and commercializing products like Mytesi[36](index=36&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=78&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses plant-based medicines, OnTarget trial results, Gelclair launch, and critical liquidity concerns [Overview](index=78&type=section&id=Overview) Jaguar Health focuses on plant-based GI medicines, with mixed OnTarget trial results, a new Gelclair launch, and orphan disease development - The OnTarget Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients did not meet its primary endpoint for all tumor types, but a prespecified subgroup analysis of breast cancer patients showed **statistical significance**[341](index=341&type=chunk) - The company entered into an exclusive 5-year in-license agreement for Gelclair, a prescription product for oral mucositis, and initiated its commercial launch in October 2024 to expand its cancer-related supportive care offerings[345](index=345&type=chunk) - Napo Therapeutics, a subsidiary, is focused on expanding crofelemer access in Europe for orphan diseases, initially targeting Short Bowel Syndrome (SBS-IF) and Microvillus Inclusion Disease (MVID)[346](index=346&type=chunk) [Results of Operations](index=91&type=section&id=Results%20of%20Operations) Revenue slightly increased, but operating expenses rose significantly due to sales and marketing for Gelclair, widening the operating loss Comparison of Results for Six Months Ended June 30 (in thousands of USD) | Item | 2025 | 2024 | Variance | Variance % | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $5,193 | $5,072 | $121 | 2.4% | | Cost of product revenue | $1,042 | $857 | $185 | 21.6% | | Research and development | $6,995 | $7,965 | $(970) | (12.2)% | | Sales and marketing | $4,960 | $2,967 | $1,993 | 67.2% | | General and administrative | $9,624 | $8,695 | $929 | 10.7% | | Loss from operations | $(17,428) | $(15,412) | $(2,016) | 13.1% | | Net loss | $(21,156) | $(18,996) | $(2,160) | 11.4% | - The increase in Sales and Marketing expense was primarily due to a **$1.1 million** increase in personnel costs and a **$0.7 million** increase in direct marketing fees to support the Gelclair launch[414](index=414&type=chunk)[418](index=418&type=chunk) - The decrease in Research and Development expense was largely due to a **$0.9 million** reduction in clinical and contract manufacturing costs as the Phase 3 OnTarget Clinical Trial concluded[413](index=413&type=chunk)[415](index=415&type=chunk) [Liquidity and Capital Resources](index=103&type=section&id=Liquidity%20and%20Capital%20Resources) Cash reserves are critically low at $2.2 million, insufficient for future operations, necessitating additional funding to avoid curtailing activities - As of June 30, 2025, the company had cash of **$2.2 million** and an accumulated deficit of **$367.4 million**[438](index=438&type=chunk)[439](index=439&type=chunk) - Management acknowledges that current capital resources are not sufficient to fund the operating plan for at least one year, and if additional financing is not obtained, the company will need to curtail planned activities and reduce costs[439](index=439&type=chunk)[441](index=441&type=chunk) Cash Flow Summary for Six Months Ended June 30 (in thousands of USD) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(13,509) | $(15,217) | | Net cash provided by financing activities | $7,621 | $24,842 | | Net increase (decrease) in cash | $(5,795) | $9,580 | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=107&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company states that quantitative and qualitative disclosures about market risk are not applicable - The company states that quantitative and qualitative disclosures about market risk are not applicable[458](index=458&type=chunk) [Item 4. Controls and Procedures](index=107&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and internal control over financial reporting were effective as of June 30, 2025 - Based on an evaluation as of June 30, 2025, the CEO and Principal Financial and Accounting Officer concluded that the company's disclosure controls and procedures were effective[460](index=460&type=chunk) - Management concluded that as of June 30, 2025, the company's internal control over financial reporting was effective based on the COSO 2013 framework[461](index=461&type=chunk) [PART II — OTHER INFORMATION](index=109&type=section&id=PART%20II.%20%E2%80%94%20OTHER%20INFORMATION) This section provides additional information including legal proceedings, risk factors, and equity security sales [Item 1. Legal Proceedings](index=109&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently subject to any material legal proceedings, though it may encounter routine legal actions - The company is not currently subject to any material legal proceedings[463](index=463&type=chunk) [Item 1A. Risk Factors](index=109&type=section&id=Item%201A.%20Risk%20Factors) Key risks include substantial minimum royalty payments starting in 2026 and potential FDA review delays impacting product approvals - The company's royalty interests require minimum royalty payments, totaling approximately **$36.0 million**, which will commence in 2026, potentially straining cash resources regardless of product sales levels[467](index=467&type=chunk)[468](index=468&type=chunk) - Disruptions at the FDA, including layoffs and the departure of senior scientists, could lead to slower review cycles and delayed approvals for the company's product candidates, materially harming the business[469](index=469&type=chunk)[472](index=472&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=111&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company conducted several unregistered equity sales, including common and preferred stock exchanges for debt, and issued warrants and convertible notes - Issued common stock and Series L and M Preferred Stock in multiple transactions to Iliad and Streeterville in exchange for reductions of outstanding royalty interest debt[473](index=473&type=chunk)[475](index=475&type=chunk)[480](index=480&type=chunk) - In a private placement on May 20, 2025, issued unregistered warrants to purchase up to **492,612** shares of common stock to institutional investors[476](index=476&type=chunk) - On June 24, 2025, completed a private exchange of approximately **$2.57 million** of new convertible promissory notes and new warrants for existing convertible notes[477](index=477&type=chunk)[478](index=478&type=chunk) [Item 6. Exhibits](index=114&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Quarterly Report on Form 10-Q, including certificates, warrants, agreements, and officer certifications

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ________ to ________ Commission File Number: 001-36338 22nd Century Group, Inc. (Exact name of registrant as specified in its charter) Nevada 98-0468420 (S ...

Exhibit 99.1 Aeries Technology, Inc. Reports Results for the Full Fiscal Year 2025 Beats Core Adjusted EBITDA Guidance, North America Revenue Up 15% Year-Over-Year. NEW YORK, July 02, 2025 - Aeries Technology, Inc. ("Aeries" or "the Company") (Nasdaq: AERT), a global leader in AI-enabled value creation, business transformation, and Global Capability Center (GCC) delivery for private equity (PE) portfolio companies, today announced financial results for the fiscal year ended March 31, 2025. As previously com ...

Financial Performance - Aeries Technology reported fiscal year 2025 revenues of $70.2 million, a decrease of 3.2% from $72.5 million in fiscal year 2024[4] - The company achieved a Core Adjusted EBITDA of $7.4 million for fiscal year 2025, representing a 365% increase compared to $1.6 million in fiscal year 2024[6] - Aeries experienced a net loss of $21.6 million in fiscal year 2025, compared to a net income of $17.3 million in fiscal year 2024[5] - Adjusted EBITDA for fiscal year 2025 was $(4.7) million, down from $9.2 million in fiscal year 2024[6] - Aeries has reiterated its revenue guidance for fiscal year 2026, projecting between $74 million and $80 million[7] - The company expects Adjusted EBITDA for fiscal year 2026 to be between $6 million and $8 million[7] Market Focus and Strategy - Aeries has exited non-core geographies, including the Middle East, to focus on its core North American market[3] - The company plans to discontinue reporting Core Adjusted EBITDA as a financial metric starting in FY2026, focusing instead on Adjusted EBITDA and GAAP results[2] Profitability and Margins - The gross profit margin for fiscal year 2025 was 24%, down from 30% in fiscal year 2024[16] Cash Flow and Assets - Cash and Cash Equivalents increased by 33% from $2,084 million in 2024 to $2,764 million in 2025[22] - Net cash used in operating activities decreased by 77%, from $(4,299) million in 2024 to $(1,009) million in 2025[22] - Total current assets decreased by 35% from $32,836 million in 2024 to $21,327 million in 2025[24] - Accounts receivable decreased significantly by 54% from $23,757 million in 2024 to $10,982 million in 2025[24] - Operating right-of-use assets increased by 31% from $7,318 million in 2024 to $9,602 million in 2025[24] - Deferred tax assets increased by 110% from $1,933 million in 2024 to $4,064 million in 2025[24] Liabilities and Shareholder Equity - Total liabilities decreased by 9% from $50,587 million in 2024 to $45,937 million in 2025[24] - Shareholders' deficit improved from $(12,240) million in 2024 to $(5,804) million in 2025, a reduction of 53%[24] Financing Activities - Net cash provided by financing activities decreased by 66%, from $7,056 million in 2024 to $2,432 million in 2025[22] Exchange Rate Effects - Effects of exchange rates on cash improved significantly by 280%, from $(64) million in 2024 to $115 million in 2025[22]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6‑K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 LG Display Co., Ltd. (Translation of Registrant's name into English) LG Twin Towers, 128 Yeoui‑daero, Yeongdeungpo‑gu, Seoul 07336, Republic of Korea (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20 ...